In K-ras wild-type metastatic colorectal cancers, cetuximab mAb was used in combination with the alphaVbeta3 (vitronectin receptor) integrin inhibitor EMD 525797, an anti-alphaV integrin subunit mAb (226) (NCT01008475). The gene discussed is KRAS; the disease is metastatic colorectal cancer.